Risks and Benefits of Statins in Lupus Erythematosus [3]

Archives of Internal Medicine

Volumn 164, Issue 1, 2004, Pages 107-108

  Noël, Bernard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AUTOANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; STATINE DERIVATIVE;

ANTIBODY PRODUCTION; APOPTOSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; DERMATOMYOSITIS; HUMAN; HYPERCHOLESTEROLEMIA; IATROGENIC DISEASE; IMMUNOLOGY; LETTER; LICHEN PLANUS; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; RASH; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 0346057969     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.1.107-b     Document Type: Letter

References (11)

1. Schattner A, Liang MH. The cardiovascular burden of lupus: a complex challenge. Arch Intern Med. 2003; 163: 1507-1510.
2. Bruce IN, Urowitz MB, Gladman DD, Hallet DC. The natural history of hypercholesterolemia in SLE. J Rheumatol. 1999;26:2137-2143.
3. Bannwarth B, Miremont G, Papapietro PM. Lupuslike syndrome associated with simvastatin [letter]. Arch Intern Med. 1992;152:1093.
4. Hanson J, Bossingham D. Lupus-like syndrome associated with simvastatin [letter]. Lancet. 1998;352:1070.
5. Srivastana M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139:45-49.
6. Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus. 2003;12:409-412.
7. Noël B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med. 2001;110:670-671.
8. Stoebner PE, Michot C, Ligeron C, Durand L, Meynadier J, Meunier L. Simvastatin-induced lichen planus pemphigoides. Ann Dermatol Venereol. 2003; 130:187-190.
9. Knapp AC, Huang J, Starling G, Kiener PA. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis. 2000;152:217-227.
10. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
11. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420:78-84.